| Bintrafusp alfa |
M-7824; GSK-4045154; MSB-0011359C |
Phase 3 Clinical |
Merck Serono |
Lung Neoplasms; Sarcoma; Cholangiocarcinoma; Breast Neoplasms; Microsatellite Instability; Vulvar Neoplasms; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Colorectal Neoplasms; Oropharyngeal Neoplasms; Thymus Neoplasms; Gallbladder Neoplasms; Adenomyoepithelioma; Lymphoma; Brain metastases; Urogenital Neoplasms; Thymoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Sarcoma, Kaposi; Triple Negative Breast Neoplasms; Solid tumours; Hematologic Neoplasms; Head and Neck Neoplasms; Intestinal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Anus Neoplasms; Stomach Neoplasms; Carcinoma; Carcinoma, Renal Cell; Esthesioneuroblastoma, Olfactory; Biliary Tract Neoplasms; Neoplasms; Colonic Neoplasms; Small Cell Lung Carcinoma; Papillomavirus Infections; Carcinoma, Transitional Cell; Nose Neoplasms; Ganglioglioma; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms |
Details
|
| Retlirafusp alfa |
SHR-1701 |
Phase 3 Clinical |
Jiangsu Hengrui Medicine Co Ltd |
Solid tumours; Esophageal Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Hodgkin Disease; Breast Neoplasms; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms |
Details
|
| Erfonrilimab |
KN046; KN-046 |
Phase 3 Clinical |
Jiangsu Alphamab Biopharmaceuticals Co Ltd |
Colorectal Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Thymoma; Esophageal Squamous Cell Carcinoma; Lymphoma; Solid tumours; Thymus Neoplasms; Breast Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Biliary Tract Neoplasms |
Details
|
| α-PD-L1/DLL3 CAR-T cell therapy(Sichuan University) |
|
Phase 3 Clinical |
Sichuan University |
Diabetes Mellitus, Type 1; Metabolic Dysfunction-Associated Steatotic Liver Disease; Small Cell Lung Carcinoma |
Details
|
| PM-8002 |
PM8002; PM-8002; BNT-327 |
Phase 3 Clinical |
Biotheus Inc |
Solid tumours; Triple Negative Breast Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Mesothelioma; Neuroendocrine Tumors; Lung Neoplasms; Carcinoma, Small Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung |
Details
|
| PD-L1 peptide vaccine (IO Biotech) |
IO-103 |
Phase 2 Clinical |
Herlev Hospital, Io Biotech Aps |
Carcinoma, Basal Cell; Smoldering Multiple Myeloma |
Details
|
| FAZ-053 |
FAZ-053; LAE-005; LAE005 |
Phase 2 Clinical |
Novartis Pharma Ag |
Solid tumours; Triple Negative Breast Neoplasms; Chordoma; Sarcoma, Alveolar Soft Part |
Details
|
| MAX-10181 |
MAX-10181; MAX-1 |
Phase 2 Clinical |
Maxinovel Pharmaceuticals Co Ltd |
Solid tumours; Neoplasms |
Details
|
| PD-L1 t-haNK cell therapy |
|
Phase 2 Clinical |
Nantkwest Inc |
Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Glioblastoma; Neoplasm Metastasis |
Details
|
| RC-98 |
RC-98; RC98 |
Phase 2 Clinical |
RemeGen Co Ltd |
Solid tumours; Stomach Neoplasms; Neoplasms |
Details
|
| Durvalumab/Gefitinib |
|
Phase 2 Clinical |
Medimmune |
Carcinoma, Non-Small-Cell Lung |
Details
|
| INCB-086550 |
INCB-086550; INCB-86550 |
Phase 2 Clinical |
Incyte Corp |
Solid tumours; Carcinoma; Carcinoma, Renal Cell; Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular |
Details
|
| BMS-936559 |
MDX-1105; BMS-936559 |
Phase 2 Clinical |
Bristol-Myers Squibb Company |
Leukemia, Myelogenous, Chronic; Shock, Septic; HIV Infections; Hodgkin Disease; Sepsis; Neoplasms; Small Cell Lung Carcinoma; Multiple Myeloma; Lymphoma, Non-Hodgkin; Melanoma |
Details
|
| PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) |
|
Phase 2 Clinical |
Changhai Hospital Of Shanghai |
Pancreatic Neoplasms |
Details
|
| PM-8001 |
6MW3111; PM-8001 |
Phase 2 Clinical |
Biotheus Inc |
Solid tumours; Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| 89Zr-durvalumab |
|
Phase 2 Clinical |
Radboud University Nijmegen |
Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| Danburstotug |
STI-3031; STI-A1015; IMC-001 |
Phase 2 Clinical |
Sorrento Therapeutics Inc |
Solid tumours; Lymphoma, T-Cell, Peripheral; Biliary Tract Neoplasms; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Lymphoma; Bacterial Infections; Neoplasm Metastasis |
Details
|
| Recombinant humanized PD-L1 monoclonal antibody (Taizhou Houde Aoke Technology) |
LP-002 |
Phase 2 Clinical |
Taizhou Houde Aoke Technology Co Ltd |
Solid tumours; Lymphoma, B-Cell; Small Cell Lung Carcinoma; Digestive System Neoplasms; Primary mediastinal B cell lymphoma; Carcinoma, Squamous Cell; Melanoma |
Details
|
| Enristomig |
ES101; INBRX-105 |
Phase 2 Clinical |
Inhibrx |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Thoracic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Nasopharyngeal Carcinoma; Oropharyngeal Neoplasms; Esophageal adenocarcinoma; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
| AP-203 |
AP-203; AP203 |
Phase 2 Clinical |
AP Biosciences Inc |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung |
Details
|
| HB-0036 |
HB-0036 |
Phase 2 Clinical |
Huabo Biopharm Co Ltd |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
| FS 118 |
FS-118 |
Phase 2 Clinical |
Merck Serono, F-Star |
Squamous Cell Carcinoma of Head and Neck; Neoplasms; Neoplasm Metastasis |
Details
|
| Acasunlimab |
PD-L1x4-1BB; DuoBody-PD-L1x4-1BB; GEN1046; BNT-311 |
Phase 2 Clinical |
Genmab A/S, Biontech Se |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms |
Details
|
| JSKN-033 |
JSKN033; JSKN-033; JSKN-003/Envafolimab |
Phase 2 Clinical |
Jiangsu Alphamab Biopharmaceuticals Co Ltd |
Solid tumours |
Details
|
| MAX-80391 |
MAX-80391; MAX-8 |
Phase 2 Clinical |
Maxinovel Pharmaceuticals Co Ltd |
Solid tumours |
Details
|
| PRS-344 |
PRS-344/ONC0055; PRS-344; PRS-344/S095012; PRS-344S095012; S-095012 |
Phase 2 Clinical |
Pieris Pharmaceuticals Inc, Laboratoires Servier |
Solid tumours |
Details
|
| Pacmilimab |
CX-072 |
Phase 2 Clinical |
Cytomx Therapeutics Inc |
Solid tumours; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Lymphoma; Melanoma |
Details
|
| BPB-101 |
BPB-101 |
Phase 2 Clinical |
Betta Pharmaceuticals Co Ltd |
Solid tumours |
Details
|
| LB-101 (Centessa Pharmaceuticals) |
LB-101 (Centessa Pharmaceuticals); LB-101 Tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibody |
Phase 2 Clinical |
Centessa Pharmaceuticals Plc |
Solid tumours |
Details
|
| AB-001 (Agastiya Biotech) |
AB01 (Agastiya Biotech); AB001 (Agastiya Biotech); AB-01 (Agastiya Biotech) |
Phase 2 Clinical |
Agastiya Biotech LLC |
Neoplasms |
Details
|
| 6MW-3511 |
6MW-3511 |
Phase 2 Clinical |
Mabwell (Shanghai) Bioscience Co Ltd |
Solid tumours; Neoplasms |
Details
|
| 18F-BMS-986229 |
18F-BMS-986229; [18F]BMS-986229 |
Phase 2 Clinical |
Bristol-Myers Squibb International Corp |
Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma |
Details
|
| sirpiglenastat |
DRP-104 |
Phase 2 Clinical |
Dracen Pharmaceuticals Inc |
Solid tumours; Fibrolamellar hepatocellular carcinoma; Carcinoma, Non-Small-Cell Lung |
Details
|
| Emfizatamab |
GNC-038 |
Phase 2 Clinical |
Sichuan Baili Pharmaceutical Co Ltd, SystImmune |
Solid tumours; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Central Nervous System Lymphoma |
Details
|
| 99mTc-NM-01 |
99mTc-NM-01 |
Phase 2 Clinical |
Nanomab Technology Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
| HB-0028 |
HB-0028 |
Phase 2 Clinical |
Huabo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd |
Solid tumours; Uterine Cervical Neoplasms |
Details
|
| PM-1022 |
PM-1022 |
Phase 2 Clinical |
Biotheus Inc |
Neoplasms |
Details
|
| PD-L1 t-haNK cell therapy/Inbakicept/Aldoxorubicin Hydrochloride(Immunitybio) |
|
Phase 2 Clinical |
Immunitybio Inc |
Pancreatic Neoplasms |
Details
|
| LBL-024 |
LBL-024; LBL024 |
Phase 2 Clinical |
Nanjing Leads Biolabs Co Ltd |
Solid tumours; Neoplasms; Carcinoma, Neuroendocrine |
Details
|
| IBC-0966 |
IBC-0966 |
Phase 2 Clinical |
SunHo (China) BioPharmaceutical Co Ltd |
Neoplasms |
Details
|
| QLF31907 |
QLF31907; QLF-31907 |
Phase 2 Clinical |
Qilu Pharmaceutical Co Ltd |
Solid tumours; Neoplasms; Carcinoma, Transitional Cell; Lymphoma, Non-Hodgkin; Melanoma |
Details
|
| INCB-099280 |
INCB-099280; INCB-99280 |
Phase 2 Clinical |
Incyte Corp Ltd |
Nasopharyngeal Carcinoma; Carcinoma, Hepatocellular; Melanoma; Uterine Cervical Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; DNA Repair-Deficiency Disorders; Colorectal Neoplasms; Microsatellite Instability; Solid tumours; Mesothelioma; Microsatellite instability-high cancer; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Neoplasms; Carcinoma, Merkel Cell; Carcinoma, Renal Cell |
Details
|
| Nebratamig |
GNC-035 |
Phase 2 Clinical |
Sichuan Baili Pharmaceutical Co Ltd |
Solid tumours; Hematologic Neoplasms; Breast Neoplasms; Metastatic breast cancer; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| Carrizumab |
|
Phase 2 Clinical |
Jiangsu Hengrui Pharmaceutical Co Ltd |
Esophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma |
Details
|
| Recombinant anti-PD-L1/TGF-β bispecific antibody |
Y101D; Y-101D |
Phase 2 Clinical |
Wuhan Yzy Biopharma Co Ltd |
Solid tumours; Pancreatic Neoplasms; Carcinoma, Hepatocellular; Adenocarcinoma |
Details
|
| 6MW-3211 |
6MW3211; 6MW-3211 |
Phase 2 Clinical |
Mabwell (Shanghai) Bioscience Co Ltd |
Carcinoma, Renal Cell; Myelodysplastic Syndromes; Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma |
Details
|
| ADG-104 |
ADG-104; ADG104 |
Phase 2 Clinical |
Guilin Sanjin Pharmaceutical Co Ltd, Adagene Inc |
Neoplasms |
Details
|
| Q-1802 |
Q-1802 |
Phase 2 Clinical |
Qiyu Biotechnology (Shanghai) Co Ltd |
Solid tumours; Esophageal Neoplasms; Gastrointestinal Neoplasms |
Details
|
| HLX-301 |
HLX-301 |
Phase 2 Clinical |
Shanghai Henlius Biologics Co Ltd |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis |
Details
|
| TQB-2858 |
TQB-2858 |
Phase 2 Clinical |
Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group |
Neoplasms; Pancreatic Neoplasms; Nasopharyngeal Neoplasms; Sarcoma; Endometrial Neoplasms; Uterine Cervical Neoplasms |
Details
|
| Sotiburafusp alfa |
HB0025; HB-0025 |
Phase 2 Clinical |
Huabo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd |
Hematologic Neoplasms; Solid tumours; Kidney Neoplasms; Carcinoma, Renal Cell; Endometrial Neoplasms; Carcinoma, Hepatocellular |
Details
|
| PD-L1 antibody combined with CTLA-4 antibody (Shanghai Zhongshan Hospital) |
|
Phase 2 Clinical |
Shanghai Zhongshan Hospital |
Cholangiocarcinoma |
Details
|
| HL-301 |
HL-301 |
Phase 2 Clinical |
Hanlim Pharm Co Ltd |
Radiation Pneumonitis; Small Cell Lung Carcinoma; Lung Neoplasms |
Details
|
| IMM-2510 |
IMM-2510 |
Phase 2 Clinical |
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd |
Solid tumours; Sarcoma |
Details
|
| PM-1003 |
PM1003 |
Phase 2 Clinical |
Biotheus Inc |
Solid tumours |
Details
|
| Lesabelimab |
BC-003 |
Phase 2 Clinical |
Guilin Sanjin Pharmaceutical Co Ltd, Adagene (Suzhou) Ltd, Dragonboat Biopharmaceutical, Baifan Biotechnology (Shanghai) Co Ltd |
Carcinoma, Renal Cell; Neoplasms; Urinary Bladder Neoplasms; Penile Neoplasms |
Details
|
| Emdifen |
|
Phase 1 Clinical |
Tianjin Chase Sun Pharmaceutical Co Ltd, Chinese Academy Of Medical Sciences |
Solid tumours |
Details
|
| 89Zr-DFO-Atezolizumab |
89Zr-DFO-Atezolizumab |
Phase 1 Clinical |
The University Of Texas Southwestern Medical Center |
Carcinoma, Renal Cell; Diagnostic agents |
Details
|
| Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) |
Z-CTLs |
Phase 1 Clinical |
Hunan Zhaotai Yongren Biotech Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
| Lodapolimab |
LY-3300054 |
Phase 1 Clinical |
Eli Lilly And Company |
Solid tumours; Skin Melanoma; Carcinoma, Renal Cell; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Microsatellite instability-high cancer; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| SL-279252 |
TAK-252; SL-279252 |
Phase 1 Clinical |
Takeda Pharmaceutical Co Ltd, Shattuck Labs Inc |
Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Non-Small-Cell Lung; Melanoma; Adenocarcinoma |
Details
|
| LOR-S03 |
CDX-527 |
Phase 1 Clinical |
Celldex Therapeutics |
Ovarian Neoplasms; Solid tumours; Liver Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Neoplasms; Microsatellite instability-high cancer; Urinary Bladder Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| MCLA-145 |
MCLA-145 |
Phase 1 Clinical |
Incyte Corp, Merus Nv |
Solid tumours; Lymphoma, B-Cell; Neoplasms |
Details
|
| CAR-T cell therapy (Timmune Biotech) |
|
Phase 1 Clinical |
Tianjin Timmune Biotech Inc |
Multiple Myeloma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
| Opucolimab |
HLX-20 |
Phase 1 Clinical |
Shanghai Henlius Biotech Inc |
Solid tumours; Neoplasms |
Details
|
| INCB-099318 |
INCB-099318; INCB-99318 |
Phase 1 Clinical |
Incyte Corp |
Neoplasms; Uterine Cervical Neoplasms; Penile Neoplasms; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Nasopharyngeal Carcinoma; Mesothelioma; Microsatellite instability-high cancer; Solid tumours; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Anus Neoplasms; Carcinoma, Merkel Cell; Ovarian Neoplasms |
Details
|
| Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology) |
|
Phase 1 Clinical |
Tianjin Mycure Medical Technology Co Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| RG-6084 |
RG-6084; RO-7191863 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Hepatitis B |
Details
|
| IMMH-010 |
IMMH-010 |
Phase 1 Clinical |
Tianjin Chase Sun Pharmaceutical Co Ltd |
Solid tumours; Neoplasms |
Details
|
| Betifisolimab |
MSB-2311 |
Phase 1 Clinical |
Mabspace Biomedicine (Suzhou) Co Ltd |
Solid tumours |
Details
|
| Simridarlimab |
IBI-322; IBI322 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Hematologic Neoplasms; Solid tumours; Bone Marrow Neoplasms; Neoplasms; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, T-Cell |
Details
|
| AB-101 (Arbutus Biopharma) |
AB-101 (Arbutus Biopharma) |
Phase 1 Clinical |
Arbutus Biopharma Corp |
Hepatitis B |
Details
|
| HLX-43 |
HLX-43; HLX43 |
Phase 1 Clinical |
Shanghai Henlius Biotech Inc |
Solid tumours |
Details
|
| SIM-0237 |
SIM-0237 |
Phase 1 Clinical |
Simcere Pharmaceutical Group Ltd |
Solid tumours; Urinary Bladder Neoplasms |
Details
|
| LP-008 |
LP-008 |
Phase 1 Clinical |
Lepu Biotech Co Ltd |
Solid tumours |
Details
|
| EMB-09 |
EMB-09 |
Phase 1 Clinical |
Shanghai Epimab Biotherapeutics, Inc |
Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung |
Details
|
| CYTO-102 |
CYTO-NK-102; CYTO-102; COH06 |
Phase 1 Clinical |
CytoImmune Therapeutics Inc |
Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| TS-1905 |
TS-1905; LY-01019; BA-1201 |
Phase 1 Clinical |
Shandong Boan Biotechnology Co Ltd |
Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Papillomavirus Infections; Carcinoma, Non-Small-Cell Lung |
Details
|
| BH-3120 |
BH-3120 |
Phase 1 Clinical |
Hanmi Pharmaceutical Co Ltd |
Solid tumours |
Details
|
| Xirestomig |
ATG-101; ATG101; YN051 |
Phase 1 Clinical |
The Origin Cell Technology Group Co Ltd |
Solid tumours; Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Neoplasm Metastasis |
Details
|
| QL-301 |
QL-301 |
Phase 1 Clinical |
Qlsf Biotherapeutics Inc |
Neoplasms |
Details
|
| MVR-C5252 |
C-5252; MVR-C5252 |
Phase 1 Clinical |
Immvira Co Ltd |
Solid tumours; Ganglioglioma; Glioblastoma; Brain Neoplasms; Glioma |
Details
|
| Q-1801 |
Q-1801; Q 1801 |
Phase 1 Clinical |
Qiyu Biotechnology (Shanghai) Co Ltd |
Solid tumours |
Details
|
| IMGS-001 |
IMGS-001 |
Phase 1 Clinical |
The University Of Texas MD Anderson Cancer Center |
Solid tumours; Neoplasms; Triple Negative Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms |
Details
|
| ABL-501 |
ABL-501 |
Phase 1 Clinical |
Abl Bio Inc |
Solid tumours |
Details
|
| CTX-8371 |
CTX-8371 |
Phase 1 Clinical |
Compass Therapeutics LLC |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Hodgkin Disease; Triple Negative Breast Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
| IBC-Ab002 |
IBC-Ab002 |
Phase 1 Clinical |
ImmunoBrain Checkpoint Inc |
Alzheimer Disease |
Details
|
| Pd-1-pik |
Pd-1-pik |
Phase 1 Clinical |
Huashan Hospital Affiliated To Fudan University |
Glioblastoma |
Details
|
| Reozalimab |
IBI-318; LY-3434172; LY3434172 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd, Eli Lilly And Company |
Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular |
Details
|
| LW-347 |
LW-347 |
Phase 1 Clinical |
Shanghai Longwood Biopharmaceuticals Co Ltd |
Neoplasms |
Details
|
| A-337 (Klus Pharma) |
A337 (Klus Pharma); A-337 (Klus Pharma) |
Phase 1 Clinical |
Klus Pharma Inc |
Neoplasms |
Details
|
| PMI-06 |
PMI06; PMI-06 |
Phase 1 Clinical |
Precision Molecular Inc |
Carcinoma, Non-Small-Cell Lung |
Details
|
| YL-222 |
YL222; YL-222 |
Phase 1 Clinical |
MediLink Therapeutics Co Ltd |
Solid tumours |
Details
|
| ND-021 |
ND-021; NM21-1480; CS-2006; CS2006 |
Phase 1 Clinical |
Numab Therapeutics Ag, Cstone Pharmaceuticals |
Solid tumours; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung |
Details
|
| SPX-303 |
SPX-303 |
Phase 1 Clinical |
SparX Biopharmaceutical Corp |
Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck |
Details
|
| KM602 |
KM602; KM-602; XZP-KM602 |
Phase 1 Clinical |
Xuanzhu (Shijiazhuang) Biotechnology Co Ltd |
Solid tumours |
Details
|
| B-901 |
B-901; B901 |
Phase 1 Clinical |
FutureGen Biopharm (Beijing) Co Ltd |
Solid tumours |
Details
|
| Recombinant anti-PD-L1/TGF-β bifunctional fusion protein |
|
Phase 1 Clinical |
Hualan Genetic Engineering (Henan) Co Ltd |
Solid tumours |
Details
|
| AUR-106 |
AUR-106 |
Phase 1 Clinical |
Aurigene Discovery Technologies Ltd |
Kidney Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| 89Zr-S095012 |
89Zr-S-095012 |
Phase 1 Clinical |
Institut De Recherches Internationales Servier |
Solid tumours |
Details
|
| RAD-204 |
RAD-204; 177Lu-RAD204 |
Phase 1 Clinical |
Radiopharm Theranostics Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
| RAD-203 |
RAD-203 |
Phase 1 Clinical |
Radiopharm Theranostics Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
| HK-010 |
HK-010; HK010 |
Phase 1 Clinical |
Anhui Anke Biotechnology (Group) Co Ltd, Hefei Hankemab Biotechnology Co Ltd |
Neoplasms |
Details
|
| Dual-targeting VEGFR1 and PD-L1 CAR-T cells Therapy (Sichuan University) |
|
Phase 1 Clinical |
Sichuan University |
Serositis; Ascites |
Details
|
| Ori-Bs-001 |
Ori-Bs-001 |
Phase 1 Clinical |
OriCell Therapeutics Co Ltd |
Solid tumours |
Details
|
| BC008-1A |
BC008-1A |
Phase 1 Clinical |
Sichuan Luzhou Buchang Biopharmaceutical Co Ltd |
Solid tumours |
Details
|
| B-1962 |
B1962; AP-505 |
Phase 1 Clinical |
AP Biosciences Inc |
Solid tumours; Liver Neoplasms; Neoplasms; Lung Neoplasms |
Details
|
| LB-1410 |
LB-1410 |
Phase 1 Clinical |
L&L Biopharma Co Ltd |
Solid tumours; Neoplasms; Lymphoma |
Details
|
| HBM-9027 |
HBM-9027; HBM9027 |
Phase 1 Clinical |
Harbour Biomed |
Solid tumours; Neoplasms |
Details
|
| QL-415 |
QL-415 |
Phase 1 Clinical |
Qlsf Biotherapeutics Inc |
Neoplasms |
Details
|
| SGN-PDL1V |
SGN-PDL1V |
Phase 1 Clinical |
Seagen Inc |
Ovarian Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
| ASC-61 |
ASC-61 |
Phase 1 Clinical |
Ascletis Pharma Inc |
Solid tumours; Neoplasms |
Details
|
| DR-30206 |
DR-30206 |
Phase 1 Clinical |
Zhejiang Doer Biologics Corp |
Solid tumours |
Details
|
| BPI-371153 |
BPI-371153 |
Phase 1 Clinical |
Betta Pharmaceuticals Co Ltd |
Solid tumours; Liver Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung |
Details
|
| CS-23546 |
CS-23546; CS23546 |
Phase 1 Clinical |
Shenzhen Chipscreen Biosciences Co Ltd |
Neoplasms; Immune System Diseases |
Details
|
| SG-1408 |
SG-1408; SG1408 |
Phase 1 Clinical |
Hangzhou Sumgen Biotechnology Co Ltd |
Solid tumours |
Details
|
| CHECKvacc |
CF33-hNIS-antiPDL1 |
Phase 1 Clinical |
Imugene Ltd, City Of Hope National Medical Center |
Triple Negative Breast Neoplasms; Breast Neoplasms; Metastatic breast cancer |
Details
|
| 706-3SBio |
SSGJ-706; 706 anti -PD1/PD -L1 BsAb; 706 anti-PD1/PD-L1 Bispecific antibody |
Phase 1 Clinical |
3sbio Inc |
Solid tumours; Composite Lymphoma; Lymphoma |
Details
|
| Gallium [68Ga] Natan recombinant PD-L1 single domain antibody |
SNA-002; 68Ga-NOTA-SNA002 |
Phase 1 Clinical |
Smartnuclide Biopharma |
Solid tumours; Neoplasms; Contrast agents |
Details
|
| SHS-009 |
SHS-009; SH009; SH-009 |
Phase 1 Clinical |
Nanjing Sanhome Pharmaceutical Co Ltd |
Neoplasms |
Details
|
| SHS-006(Nanjing Sanhome Pharmaceutical) |
SHS-006; SH-006; SH006 |
Phase 1 Clinical |
Nanjing Sanhome Pharmaceutical Co Ltd |
Solid tumours |
Details
|
| CN-202 |
CN-202 |
Phase 1 Clinical |
Curon Biopharmaceutical Ltd |
Hematologic Neoplasms; Solid tumours; Neoplasm Metastasis |
Details
|
| Recombinant oncolytic type II herpes simplex virus (Binhui Biopharmaceutical) |
BS-006; oHSV2-BiTEs |
Phase 1 Clinical |
Wuhan Binhui Biotechnology Co Ltd |
Solid tumours; Neoplasms; Melanoma; Uterine Cervical Neoplasms |
Details
|
| FS-222 |
FS-222 |
Phase 1 Clinical |
F-star Beta Ltd |
Neoplasms; Neoplasm Metastasis |
Details
|
| IMM-2520 |
IMM-2520 |
Phase 1 Clinical |
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| BAT-7104 |
BAT-7104 |
Phase 1 Clinical |
Bio-Thera Solutions Ltd |
Solid tumours; Neoplasms |
Details
|
| CA-170 |
CA-170; AUPM-170 |
Phase 1 Clinical |
Aurigene |
Solid tumours |
Details
|
| FH-2001 |
FH-2001 |
Phase 1 Clinical |
Shanghai Fosun Pharmaceutical Industrial Development Co Ltd |
Solid tumours |
Details
|
| TT-00420/Atezolizumab |
|
Phase 1 Clinical |
TransThera Sciences (Nanjing) Inc |
Gastrointestinal Neoplasms |
Details
|
| PF-07257876 |
|
Phase 1 Clinical |
Pfizer Inc |
Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung |
Details
|
| AN-4005 |
AN-4005 |
Phase 1 Clinical |
Hangzhou Adlai Nortye Biopharma Co Ltd |
Solid tumours; Neoplasms; Lymphoma |
Details
|
| BR-102 |
BR102 |
Phase 1 Clinical |
BioRay Pharmaceutical Co Ltd |
Solid tumours; Neoplasms |
Details
|
| TST-005 |
TST-005; TST005 |
Phase 1 Clinical |
Mabspace Biomedicine (Suzhou) Co Ltd |
Solid tumours; Neoplasms; Papillomavirus Infections |
Details
|
| GT-90008 |
GS-19-PLB-1C; GT-90008; GS-19 |
Phase 1 Clinical |
Suzhou Koshine Biomedica Inc |
Solid tumours |
Details
|
| TJ-L14B |
ABL-503; TJ-L14B/ABL503; ABL503 |
Phase 1 Clinical |
I-Mab Biopharma Co Ltd |
Solid tumours |
Details
|
| CCX-559 |
CCX-559 |
Phase 1 Clinical |
Chemocentryx Inc |
Solid tumours; Neoplasms |
Details
|
| Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University) |
|
Phase 1 Clinical |
Sichuan University |
Peritoneal Neoplasms; Pleural Effusion, Malignant |
Details
|
| QLS31901 |
QLS-31901; QLS31901 |
Phase 1 Clinical |
Qilu Pharmaceutical Co Ltd |
Neoplasms |
Details
|
| IMM2505 |
IMM2505; IMM-2505 |
Phase 1 Clinical |
SunHo (China) BioPharmaceutical Co Ltd, ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd |
Solid tumours |
Details
|
| SKB-337 |
SKB337; A-337; SKB-337 |
Phase 1 Clinical |
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd |
Solid tumours |
Details
|
| GNC-039 |
GNC-039 |
Phase 1 Clinical |
Sichuan Baili Pharmaceutical Co Ltd |
Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis |
Details
|
| ABSK-043 |
ABSK043 |
Phase 1 Clinical |
ABbisko Therapeutics Co Ltd |
Solid tumours; Neoplasms |
Details
|
| IBI-323(Innovent Biologics) |
IBI-323 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Neoplasms |
Details
|
| KN-052 |
KN-052 |
Phase 1 Clinical |
Suzhou Alphamab Co Ltd |
Solid tumours |
Details
|
| SG12473 |
SG12473; SG-12473 |
Phase 1 Clinical |
Hangzhou Sumgen Biotechnology Co Ltd |
Hematologic Neoplasms; Solid tumours; Neoplasms |
Details
|
| BJ-005 |
BJ-005 |
Phase 1 Clinical |
Boji Biomedical Technology (Hangzhou) Co Ltd |
Solid tumours; Lymphoma |
Details
|
| MT-6402 |
MT-6402; MT-64-6402 |
Phase 1 Clinical |
Molecular Templates Inc |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung |
Details
|
| FPT-155 |
CD80-Fc; FPT-155 |
Phase 1 Clinical |
Five Prime Therapeutics Inc |
Solid tumours |
Details
|
| Garivulimab |
BGB-A333 |
Phase 1 Clinical |
Beigene Ltd |
Solid tumours; Neoplasms |
Details
|
| Recombinant anti-PD-L1 human monoclonal antibody (Jiansu huaiyu) |
|
Phase 1 Clinical |
Jiangsu Huaiyu Pharmaceutical Co Ltd |
Solid tumours |
Details
|
| Durvalumab/Selumetinib sulfate |
|
Phase 1 Clinical |
Astrazeneca Plc |
Neoplasms |
Details
|
| 18F-BMS-986192 |
BMS-986192-[18F] |
Clinical |
Bristol-Myers Squibb Company |
Neoplasms |
Details
|
| 89Zr-KN035（Wuxi No. 4 People's Hospital） |
|
Clinical |
Wuxi No. 4 People |
Solid tumours |
Details
|
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one. 
A-Z
